MAIA.US MAIA Biotechnology Inc.

Healthcare Biotechnology USA Stocks
1.00 USD
Close of Nov 15, 2026
0.8700 3.19
Market cap
USD 61.8M
P/E
-
P/B
4.21x
ROE
-195.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MAIA.US undervalued?

Graham number

The Graham number of MAIA Biotechnology Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MAIA Biotechnology Inc. fundamental analysis

No fundamental analysis for MAIA Biotechnology Inc. yet.

MAIA Biotechnology Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MAIA Biotechnology Inc.

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Full company profile